**Table S1:** Comparison of SA patients on biologics (anti-IL5 or anti-IgE) with or without chronic OCS treatment (n=270)

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | No chronic OCS use  | Chronic OCS use | P-value |
| N (%) | 203 (75) | 67 (25) | N/A |
| Gender: F (%) | 123 (61) | 25 (37) | 0.001 |
| Age  | 53 ± 16 | 53 ± 15 | 0.5938 |
| Age of onset (%)<12 yr12-40 yr≥40 yr | 67 (33)73 (36)61 (30) | 16 (24)24 (36) 26 (39) | 0.287 |
| BMI  | 27 ± 6 | 26 ± 4 | 0.1152 |
| Smoking History: Never (%)Current (%)Ex (%) | 133 (66)12 (6)58 (29) | 42 (63)2 (3)23 (34) | 0.522 |
| Atopic status: y (%)  | 169 (83) | 45 (67) | 0.005 |
| SABA: y (%)  | 177 (87) | 56 (84) | 0.289 |
| LABA: y (%)  | 203 (100) | 67 (100) | 1 |
| LAMA: y (%)  | 10 (5) | 3 (4) | 0.591 |
| OCS dose (median IQR) (%)<44-88-16>16 mg/d | N/A | 13 (19)22 (33)22 (33)10 (15) | N/A |
| ACT  | 15.8 ± 5.6 | 13.7 ± 5.7 | 0.0254 |
| ACQ  | 2.3 ± 1.8 | 2.5 ± 1.5 | 0.6997 |
| AQLQ  | 4.5 ± 1.4 | 4.2 ± 1.6 | 0.3713 |
| Exacerbations in last 12 months  | 1 (0 - 3) | 2 (1 - 4) | 0.0009 |
| Number of hospitalizations in last year  | 1 (0 - 1) | 1 (0 - 1) | 0.3124 |
| Near fatal episodes last year  | 0 (0 - 0) | 0 (0 - 1) | 0.8865 |
| Death: (%)  | 3 (1) | 1 (1) | 0.683 |
| FEV1 (L)  | 2.01 ± 0.81 | 2.16 ± 0.85 | 0.2142 |
| FEV1 (% predicted)  | 70 ± 19 | 66 ± 21 | 0.1880 |
| FVC (% predicted)  | 89 ± 18 | 89 ± 21 | 0.8730 |
| FEV1/FVC (% predicted)  | 63 ± 12 | 61 ± 13 | 0.1647 |
| FEV1 Reversibility  | 11 ± 15 | 13 ± 13 | 0.0732 |
| DLCO (%)  | 85 ± 21 | 81 ± 20 | 0.3709 |
| PC20M Value (mg/ml)  | 0.21 (0.16 – 0.93) | 0.07 (0.04 - 2.00) | 0.4054 |
| Total serum IgE (kU/l)  | 298 (136-591) | 300 (156-585) | 0.9608 |
| Blood Eosinophils (/mm3) | 269 (100-570) | 340 (126-650) | 0.2997 |
| Blood Eosinophils (/mm3) <150150-300300-400>400 | 52 (33)31 (19)13 (8)60 (38) | 16 (31)5 (9)8 (15)23 (44) | 0.189 |
| Sputum eosinophils (%) (n=28) | 7 (1 - 27) | 0 (1 -3) | 0.0191 |
| Sputum neutrophils (%) (n=28) | 32 (17 – 66) | 72 (60 – 81) | 0.0054 |
| Exhaled NO (50 ml/sec) (ppb)  | 26 (13 - 51) | 30 (17 - 79) | 0.1249 |
| Emphysema  | 11 (5) | 3 (5) | 0.212 |
| Bronchiectasis  | 28 (14) | 12 (18) | 0.223 |
| Rhinosinusitis  | 107 (53) | 33 (50) | 0.617 |
| Nasal polyposis  | 50 (26) | 17 (26) | 0.702 |
| Overweight or obesity  | 102 (50) | 30 (45) | 0.705 |
| Psychopathology  | 39 (19) | 9 (13) | 0.667 |
| GERD  | 67 (33) | 25 (38) | 0.618 |
| ABPA  | 13 (6) | 5 (8) | 0.286 |
| EGPA (Churg Strauss)  | 11 (5) | 4 (6) | 0.563 |
| Occupational asthma  | 6 (3) | 3 (5) | 0.877 |